Why did BOT.AX stock drop so sharply on 17 Feb 2026?

BOT.AX stock fell **42.61%** amid heavy selling and high volume as investors positioned ahead of a **4 Mar 2026** earnings announcement and weighed clinical, funding and dilution risk for Botanix Pharmaceuticals Limited.

What is Meyka AI's price forecast for BOT.AX stock?

Meyka AI's model projects **monthly A$0.12** and **quarterly A$0.08** for BOT.AX stock. These imply **81.82%** and **21.21%** upside from A$0.066. Forecasts are model-based projections and not guarantees.

Is BOT.AX stock a buy after the sell-off?

Meyka AI assigns BOT.AX a **B (HOLD)** grade. Given negative EPS, heavy volatility and an upcoming earnings event, the stock is higher risk. Traders should use strict risk controls and confirm any thesis with the March results.

What are the key technical levels for BOT.AX stock?

Key levels: immediate support **A$0.066**, short-term resistance **A$0.075**, and moving average resistance near **A$0.12** (50-day). RSI **43.70** and ADX **19.23** show no clear trend, so expect range trading until catalysts arrive.

AU Stocks

BOT.AX stock falls 42.61% to A$0.066 on ASX 17 Feb 2026: watch March earnings

ByHuzaifa Zahoor February 17, 2026February 17, 2026

BOT.AX stock plunged 42.61% to A$0.066 on the ASX on 17 Feb 2026, trading 90,907,784 shares as investors reacted ahead of a scheduled earnings announcement. The fall leaves Botanix Pharmaceuticals Limited (BOT.AX) well below its 50-day average of A$0.12195 and 200-day average of A$0.17871, reflecting heavy selling pressure in the biotech sector. With an upcoming earnings date on 4 Mar 2026, traders are pricing higher execution and clinical risks. We break down drivers, valuation, technicals and Meyka AI forecasts to frame risk and opportunity for short-term active traders.